Mika K. Derynck

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Debashis Sarker, Joo Ern Ang, Richard D. Baird et al. · Clinical Cancer Research · 2014 · 341 citations · Full text

Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes

Jen-Chywan Wang, Mika K. Derynck, Daisuke Nonaka et al. · Proceedings of the National Academy of Sciences · 2004 · 315 citations · Full text

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Jill M. Spoerke, Steven Gendreau, Kimberly Walter et al. · Nature Communications · 2016 · 292 citations · Full text

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Ian E. Krop, Ingrid A. Mayer, Vinod Ganju et al. · The Lancet Oncology · 2016 · 288 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +8

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Michael S. Gordon, Daniela Matei, Carol Aghajanian et al. · Journal of Clinical Oncology · 2006 · 249 citations